Back to top

[ Skip to main content ]

The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.

“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.

The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.

“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.

“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”

Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.

“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”

The Psychoactive Substances Act key points

  • Sets up a legal framework for the testing, manufacture, sale and regulation of psychoactive products.
  • Includes health and harm minimisation in the purpose of the act.
  • Products will no longer be sold in dairies, grocery stores etc. People and businesses will need a license to sell the products.
  • Restrictions on advertising and marketing and the purchase age (18+)
  • Like alcohol, councils will have the option of developing local policies around where stores can be located.
  • Products will undergo rigorous clinical testing to determine whether they are ‘low risk’.
  • Clear rules around use of animal testing. Animal testing can only be used if there is no alternative.
  • If proven a product is ‘low risk’ of harm then as long as a person meets certain criteria (e.g. person of good repute, NZ citizen) a three year licence to sell that product can be granted.
  • Products which appear to cause more harm than clinical testing showed can be pulled from the market.
  • A register of all approved and unapproved products will be publically available.
  • A code of practice will be in place within 6 months.

Check out these related articles: See more articles

Police discretion for drug offences needs greater health funding

Greater funding for health and social services is urgently needed for changes to Misuse of Drugs Act to be effective....

Read More

How synthetics became a public health crisis

How we got here was not by accident, but due to a series of legal changes with unintended consequences. Samuel Andrews explains how the synt......

Read More

Government action on synthetics drugs crisis applauded

The Government’s response to synthetic drug deaths is welcomed by the Drug Foundation. This is an important step towards treating drug use a......

Read More
MoS Nov 2018 thumbnail shamubeel eaqub

Q&A: Costing drug policy options

Economist Shamubeel Eaqub talks to Emma Espiner about a new report that makes the case for a health-based approach to drug policy as not onl......

Read More
Share:
e substance newsletter promotional thumbnail
Subscribe to email updates

Get regular news, analysis and commentary on drugs issues in New Zealand. Free.

Sign up now!

Did You Know resources thumbnail
Talk drugs with young people

Did You Know helps you talk with a young person about drugs -- videos, posters and conversation starter.

Get started